Our expert team will determine if GLP-1 medications are right for you and will create a customized plan tailored to your needs
Evaluate biosimilars for injectables (liraglutide, dulaglutide, semaglutide) using similarity studies for quality, safety, immunogenicity, and sometimes clinical trials.[11] Monitor post-marketing safety, especially when many brands enter the market in a short time.[6] When done well, this approach gives India the best of both worlds: lower prices through Indian manufacturing, and safety through strong regulation
In the ubiquitin-independent pathway, specific receptor proteins such as BCL2 interacting protein 3 (BNIP3)/ BCL2 interacting protein 3 like (BNIP3L), FUNDC1, and AMBRA1 recruit LC3 to facilitate mitochondria degradation [7]
Patients who receive and consistently take the medication report results consistent with clinical trial data: 10 to 15% body weight loss over 6 to 12 months on semaglutide, and up to 20%+ on tirzepatide
Most noticeable after dose increases